A Phase 2 interventional study of heat-labile enterotoxin of E. coli (LT) and Placebo in Prevention of Travelers' Diarrhea, sponsored by Intercell USA, Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-29.
Sponsored by Intercell USA, Inc. (part of Valneva) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 249 studies in Diarrhea with a site in United States — 15 open to participants now, 20 under way, none of them phase 3. Diarrhea · United States.
Among the 249 studies in Diarrhea with a site in United States, this one is the 72nd largest by enrollment of the 223 interventional ones that give a count, is one of 9 that started in 2008, is one of 64 in phase 2, and was the 70th registered.
879 studies on the registry are indexed under Diarrhea; 78 are open to participants now.
Browse Diarrhea studies →15 of the 249 studies in Diarrhea with a site in United States are open now. Recruiting first, the newest first:
Virginia Polytechnic Institute and State University · Sites in United States
Ages 6 mo+ · Healthy volunteers
Maryam Lustberg · Sites in United States
Ages 18+ · Healthy volunteers
Eli Lilly and Company · Sites in United States, Belgium, Canada and 7 more countries
Ages 18–75
Bausch Health Americas, Inc. · Sites in United States
Ages 6–12
Peach Perfect · Sites in United States
Ages 18–60
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 45 Diarrhea studies recruiting now, 21 (47%) set no upper age limit and 22 (49%) stop at 75 or younger; 19 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
249 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 46 · Phase 2 80 · Phase 3 43 · Phase 4 24
First in 1996; this study’s year is marked. 9 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 120 is below the median of 138 across 739 interventional studies indexed under Diarrhea.
Median enrollment 63 across the 223 interventional studies, 190 across the 16 observational. Of the 213 that completed or were terminated, 95 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
99 of 249 have an industry lead sponsor. The 10 most frequent:
This study is registered under Intercell USA, Inc., one of the names counted as Valneva. Under that name alone:
Intercell USA, Inc. is the lead sponsor of 10 studies on the registry; none are open to participants now.
Valneva has 8 studies filed under Diarrhea — fewer than ten, so there is no comparison to draw.
10 of the studies in Diarrhea with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01822470Indiana UniversitySmall Intestinal Bacterial Overgrowth: A Prospective Registry | 2026-12 |
| NCT05465629ViomeViome Nutritional Programs to Improve Clinical Outcomes for Gastrointestinal Conditions | 2026-12 |
| NCT06684470Mayo ClinicNovel Pilot Study to Treat Symptoms of IBS With Diarrhea Using Combination Therapy of a Low-FODMAP Diet and a Neuromodulator | 2026-12-19 |
| NCT06801067Memorial Sloan Kettering Cancer CenterA Study of SER-155 to Treat Diarrhea in People on Immunotherapy | 2027-01-24 |
| NCT04826991Temple UniversityWells and Enteric Disease Transmission | 2027-03-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 249 studies in Diarrhea with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate and compare the immune responses and safety following a two vaccination regimen by transcutaneous immunization with heat-labile enterotoxin of E. coli (LT) patches or placebo patches.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
80 subjects will receive a two vaccination regimen with a LT patch.
Biological: heat-labile enterotoxin of E. coli (LT)
40 subjects will receive a two vaccination regimen with a placebo patch.
Biological: Placebo
Travelers' Diarrhea Vaccine System
Also known as: TD Vaccine System
Travelers' Diarrhea Vaccine System
Also known as: TD Vaccine System
Geometric Mean Titer (GMT) After First and Second Vaccination With LT Vaccine Patch and Comparison Against Placebo
Time frame: Day 0, Day 14, Day 21, Day 28, Day 35, Day 90, Day 194
Geometric Mean Fold Ratio (GMFR) After First and Second Vaccination With LT Vaccine Patch and Comparison Against Placebo
GMFRs relative to the baseline titer were determined at each post-baseline time point. All GMFRs were based on log10-transformed data.
Time frame: Day 14, Day 21, Day 28, Day 35, Day 90, Day 194
Seroconversion (SCR) After First and Second Vaccination With LT Vaccine Patch and Comparison Against Placebo
Definition of SCR: * Seroconversion IgG: ≥ 2-fold rise of LT IgG titer relative to baseline * Seroconversion IgA: ≥ 4-fold rise of LT IgA titer relative to baseline
Time frame: Day 14, Day 21, Day 28, Day 35, Day 90, Day 194
Evaluation of Safety of LT Vaccine Patch After First and Second Vaccination Compared to Placebo Patch
LT subjects (Group 1) were followed for six months longer (until Day 380) than Placebo subjects (Group 2) (until Day 194)
Time frame: 13 months
Evaluation of Residual LT in the Patch and on the Skin at the Patch Site Post-wear
Time frame: 1 month
Evaluation of LT-specific Immune Responses One-year After Original Treatment Regimen in LT Patch Group
GMT
Time frame: 13 months
Evaluation of LT-specific Immune Responses One Year After Original Treatment Regimen in LT Patch Group
GMFR
Time frame: 13 months
Evaluation of LT-specific Immune Responses One Year After Original Treatment Regimen in LT Patch Group
SCR
Time frame: 13 months
| Milestone | Group 1: 37.5 µg LT Patch | Group 2: 0 µg LT Patch (Placebo) |
|---|---|---|
| Started | 81 | 39 |
| Completed | 70 | 36 |
| Not completed | 11 | 3 |
| geometric mean titer | Group 1: 37.5 µg LT Patch | Group 2: 0 µg LT Patch (Placebo) |
|---|---|---|
| GMT LT IgG - Day 0 | 432.6 (349.0 to 536.2) | 400.5 (290.5 to 552.2) |
| GMT LT IgG - Day 14 | 4477.5 (3249.6 to 6169.4) | 490.6 (303.8 to 792.2) |
| GMT LT IgG - Day 21 | 9107.7 (6791.9 to 12213.0) | 462.1 (298.0 to 716.6) |
| GMT LT IgG - Day 28 | 13411.9 (10420 to 17263.5) | 372.6 (255.4 to 543.4) |
| GMT LT IgG - Day 35 | 15024.3 (11893 to 18979.4) | 383.6 (270.5 to 544.0) |
| GMT LT IgG - Day 90 | 6823.7 (5553.1 to 8385.1) | 156.2 (114.5 to 213.1) |
| GMT LT IgG - Day 194 | 2489.2 (1965.5 to 3152.4) | 100.2 (70.7 to 142.0) |
| GMT LT IgA - Day 0 | 49.4 (37.4 to 65.1) | 58.9 (38.9 to 89.1) |
| GMT LT IgA - Day 14 | 395.6 (289.9 to 539.8) | 59.1 (37.2 to 94.1) |
| GMT LT IgA - Day 21 | 619.2 (466.2 to 822.4) | 60.9 (39.8 to 93.0) |
| GMT LT IgA - Day 28 | 780.0 (603.8 to 1007.7) | 53.9 (36.8 to 79.1) |
| GMT LT IgA - Day 35 | 681.2 (526.1 to 882.0) | 52.5 (35.7 to 77.3) |
| GMT LT IgA - Day 90 | 348.1 (280.3 to 432.4) | 40.5 (29.2 to 56.1) |
| GMT LT IgA - Day 194 | 177.0 (145.3 to 215.5) | 32.6 (24.3 to 43.6) |
GMFRs relative to the baseline titer were determined at each post-baseline time point. All GMFRs were based on log10-transformed data.
| ratio | Group 1: 37.5 µg LT Patch | Group 2: 0 µg LT Patch (Placebo) |
|---|---|---|
| GMFR LT IgG - Day 14 | 10.4 (7.4 to 14.5) | 1.2 (0.7 to 2.0) |
| GMFR LT IgG - Day 21 | 21.1 (15.2 to 29.2) | 1.2 (0.7 to 1.9) |
| GMFR LT IgG - Day 28 | 31.0 (23.5 to 41.0) | 0.9 (0.6 to 1.4) |
| GMFR LT IgG - Day 35 | 34.7 (26.6 to 45.4) | 1.0 (0.6 to 1.4) |
| GMFR LT IgG - Day 90 | 16.0 (12.4 to 20.8) | 0.4 (0.3 to 0.6) |
| GMFR LT IgG - Day 194 | 5.7 (4.3 to 7.5) | 0.2 (0.2 to 0.4) |
| GMFR LT IgA - Day 14 | 8.0 (5.8 to 11.0) | 1.0 (0.6 to 1.6) |
| GMFR LT IgA - Day 21 | 12.5 (9.3 to 16.8) | 1.0 (0.7 to 1.6) |
| GMFR LT IgA - Day 28 | 15.8 (12.1 to 20.7) | 0.9 (0.6 to 1.4) |
| GMFR LT IgA - Day 35 | 13.8 (10.6 to 17.9) | 0.9 (0.6 to 1.3) |
| GMFR LT IgA - Day 90 | 7.1 (5.5 to 9.2) | 0.6 (0.4 to 1.0) |
| GMFR LT IgA - Day 194 | 3.4 (2.6 to 4.6) | 0.5 (0.3 to 0.8) |
Definition of SCR: * Seroconversion IgG: ≥ 2-fold rise of LT IgG titer relative to baseline * Seroconversion IgA: ≥ 4-fold rise of LT IgA titer relative to baseline
| percentage of participants | Group 1: 37.5 µg LT Patch | Group 2: 0 µg LT Patch (Placebo) |
|---|---|---|
| SCR LT IgG - Day 14 | 77.6 (66.6 to 86.4) | 8.8 (1.9 to 23.7) |
| SCR LT IgG - Day 21 | 89.5 (80.3 to 95.3) | 8.8 (1.9 to 23.7) |
| SCR LT IgG - Day 28 | 97.4 (90.8 to 99.7) | 2.9 (0.1 to 15.3) |
| SCR LT IgG - Day 35 | 97.4 (90.8 to 99.7) | 5.9 (0.7 to 19.7) |
| SCR LT IgG - Day 90 | 98.7 (92.8 to 100) | 9.1 (1.9 to 24.3) |
| SCR LT IgG - Day 194 | 83.3 (72.7 to 91.1) | 0 (0 to 10.6) |
| SCR LT IgA - Day 14 | 57.9 (46.0 to 69.1) | 0.0 (0.0 to 10.3) |
| SCR LT IgA - Day 21 | 71.1 (59.5 to 80.9) | 0.0 (0.0 to 10.3) |
| SCR LT IgA - Day 28 | 82.9 (72.5 to 90.6) | 0.0 (0.0 to 10.3) |
| SCR LT IgA - Day 35 | 81.6 (71.0 to 89.5) | 2.9 (0.1 to 15.3) |
| SCR LT IgA - Day 90 | 68.0 (56.2 to 78.3) | 3.0 (0.1 to 15.8) |
| SCR LT IgA - Day 194 | 50.0 (38.0 to 62.0) | 0.0 (0.0 to 10.6) |
LT subjects (Group 1) were followed for six months longer (until Day 380) than Placebo subjects (Group 2) (until Day 194)
| Participants | Group 1: 37.5 µg LT Patch | Group 2: 0 µg LT Patch (Placebo) |
|---|---|---|
| AEs : All AEs - vaccination 1 | 75 | 26 |
| AEs : All AEs - vaccination 2 | 76 | 24 |
| AEs : Local AEs - vaccination 1 | 73 | 19 |
| AEs : Systemic AEs - vaccination 1 | 43 | 18 |
| AEs : Local AEs - vaccination 2 | 73 | 13 |
| AEs : Systemic AEs - vaccination 2 | 44 | 18 |
| Severe AEs : All AEs - vaccination 1 | 2 | 2 |
| Severe AEs : All AEs - vaccination 2 | 2 | 0 |
| Severe AEs : Local AEs - vaccination 1 | 0 | 0 |
| Severe AEs : Systemic AEs - vaccination 1 | 2 | 2 |
| Severe AEs : Local AEs - vaccination 2 | 0 | 0 |
| Severe AEs : Systemic AEs - vaccination 2 | 2 | 0 |
| AEs requiring Treatment : All AEs - vaccination 1 | 24 | 6 |
| AEs requiring Treatment : All AEs - vaccination 2 | 33 | 10 |
| AEs requiring Treatment : Local AEs - vacc. 1 | 10 | 0 |
| AEs requiring Treatment : Systemic AEs - vacc. 1 | 16 | 6 |
| AEs requiring Treatment : Local AEs - vacc. 2 | 4 | 0 |
| AEs requiring Treatment : Systemic AEs - vacc. 2 | 31 | 10 |
| related AEs : All AEs - vaccination 1 | 74 | 20 |
| related AEs : All AEs - vaccination 2 | 74 | 13 |
| related AEs : Local AEs - vaccination 1 | 73 | 19 |
| related AEs : Systemic AEs - vaccination 1 | 17 | 5 |
| related AEs : Local AEs - vaccination 2 | 73 | 13 |
| related AEs : Systemic AEs - vaccination 2 | 6 | 3 |
| Serious AEs : All AEs - vaccination 1 | 0 | 1 |
| Serious AEs : All AEs - vaccination 2 | 1 | 1 |
| Serious AEs : Local AEs - vaccination 1 | 0 | 0 |
| Serious AEs : Systemic AEs - vaccination 1 | 0 | 1 |
| Serious AEs : Local AEs - vaccination 2 | 0 | 0 |
| Serious AEs : Systemic AEs - vaccination 2 | 1 | 1 |
| nanograms (ng) | Group 1: 37.5 µg LT Patch |
|---|---|
| Residual LT in the Patch (ng LT) | 15893 ± 6980 |
| Residual LT in the Swab (ng LT) | 7231 ± 2939 |
| Estimate of LT Delivered (ng LT) | 14376 ± 7609 |
GMT
| GMT | Group 1: 37.5 µg LT Patch |
|---|---|
| GMT LT IgG - Day 380 | 1653.7 (1377.9 to 1984.8) |
| GMT LT IgA - Day 380 | 122.3 (98.3 to 152.1) |
GMFR
| ratio | Group 1: 37.5 µg LT Patch |
|---|---|
| GMFR LT IgG - Day 380 | 3.8 (3.0 to 4.9) |
| GMFR LT IgA - Day 380 | 2.4 (1.8 to 3.3) |
SCR
| percentage of participants | Group 1: 37.5 µg LT Patch |
|---|---|
| SCR LT IgG - Day 380 | 67.1 (54.9 to 77.9) |
| SCR LT IgA - Day 380 | 38.6 (27.2 to 51.0) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: 37.5 µg LT Patch | — | 1/81 (1.2%) | 79/81 (97.5%) |
| Group 2: 0 µg LT Patch (Placebo) | — | 2/39 (5.1%) | 32/39 (82.1%) |
| Event | Group 1: 37.5 µg LT Patch | Group 2: 0 µg LT Patch (Placebo) |
|---|---|---|
| Haemorrhoidal haemorrhageGastrointestinal disorders | 0/81 | 1/39 |
| GastroenteritisInfections and infestations | 0/81 | 1/39 |
| Non-cardiac chest painGeneral disorders | 1/81 | 0/39 |
| Event | Group 1: 37.5 µg LT Patch | Group 2: 0 µg LT Patch (Placebo) |
|---|---|---|
| Application site rashInjury, poisoning and procedural complications | 77/81 | 5/39 |
| Application site erythemaInjury, poisoning and procedural complications | 72/81 | 14/39 |
| Application site pruritusInjury, poisoning and procedural complications | 72/81 | 8/39 |
| Application site discolourationInjury, poisoning and procedural complications | 62/81 | 5/39 |
| Application site painInjury, poisoning and procedural complications | 22/81 | 3/39 |
| DiarrhoeaGastrointestinal disorders | 11/81 | 4/39 |
| Application site oedemaInjury, poisoning and procedural complications | 11/81 | 0/39 |
| Upper respiratory tract infectionInfections and infestations | 7/81 | 4/39 |
| Blood glucose increasedInvestigations | 6/81 | 3/39 |
| Protein urine presentInvestigations | 4/81 | 3/39 |
Intent-to-Treat (ITT) Population: all study subjects who were consented, randomized, and had a baseline serology
| Age, Continuous(years) | Group 1: 37.5 µg LT Patch | Group 2: 0 µg LT Patch (Placebo) | Total |
|---|---|---|---|
| Mean | 34.1 ± 10.2 | 35.3 ± 13.0 | 34.5 ± 11.2 |
| Sex: Female, Male(Participants) | Group 1: 37.5 µg LT Patch | Group 2: 0 µg LT Patch (Placebo) | Total |
|---|---|---|---|
| Female | 46 | 26 | 72 |
| Male | 35 | 13 | 48 |
The record gives a start of Sep 2008, a primary completion of Nov 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2014, 4 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.